Bausch Health (NYSE:BHC) announced today that it initiated a clinical trial program in Canada to investigate the use of Virazole for treating COVID-19. With today’s announcement, Bausch joins Eli Lilly (NYSE:LLY) and Care Access Research, which both announced clinical testing of coronavirus therapies last week. Bausch’s Virazole is currently approved in the U.S. and Canada, among other […]
Business/Financial News
Qosina touts single-use bioprocessing components for coronavirus response
With the bioprocess industry mobilizing to support the development of tests, vaccines and treatments for COVID-19, medtech distributor Qosina said that its supply of single-use bioprocessing components can offer significantly reduced time to clinic and market over multi-use systems during situations like the coronavirus pandemic. Ronkokoma, N.Y.-based Qosina said it also provides 3D CAD models and […]
OncoSec, Inovio testing COVID-19 vaccines
OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]
Nemaura Medical enters non-binding agreements for its SugarBeat platform
Nemaura Medical (NSDQ:NMRD) announced today that it entered into multiple verbal non-binding agreements for its SugarBeat continuous glucose monitor as it seeks to secure regional and global partnerships. The Loughborough, U.K.–based company expects the agreements to lead to discussions over licensing and collaboration, but can’t guarantee that deals will be struck as planned, or at all, […]
Insulet down after hours on Q4 sales beat, bottom-line slide
Insulet (NSDQ:PODD) shares sunk after hours today on fourth-quarter results that beat the consensus forecast for revenue but appeared to miss on earnings. The Acton, Mass.–based insulin delivery device maker posted profits of $5 million, or 8¢ per share, on sales of $209.4 million for the three months ended Dec. 31, 2019, for a 49.5% bottom-line […]
Eitan Group appoints new Q Core Medical CEO
Eitan Group today said it appointed Igal Shany as CEO of its Q Core Medical and president of Eitan Group. Shany has previously served on the board of directors for Q Core and sites on the board for Eitan’s other infusion companies Sorrel Medical and Avoset Health. “I’ve had the pleasure of working with Eitan […]
Wearable insulin delivery device maker Valeritas files for Chapter 11, selling company
Valeritas (NSDQ:VLRX) announced that the company and its subsidiaries filed voluntary petitions for Chapter 11 bankruptcy, having agreed to sell substantially all of the business to Zealand Pharma (CPH:ZEAL). The agreement is slated to provide a total cash consideration of $23 million along with certain liabilities related to the ongoing business. Once the acquisition is completed, Zealand plans […]
Senseonics, Companion Medical to integrate sensor glucose and insulin data
Senseonics (NYSE:SENS) will integrate its Eversense continuous glucose monitoring (CGM) system’s real-time glucose data with Companion Medical‘s InPen smart insulin delivery system. The agreement between Senseonics and Companion, announced today, is slated to bring the technologies together to allow real-time glucose data to be continuously incorporated into the InPen insulin system. This is designed to allow for more […]
Rani Therapeutics could go the IPO route
Rani Therapeutics is reportedly moving forward with an early-stage efficacy and safety study for its robotic pills and may be on its way toward the possibility of an IPO. According to a report in Endpoints News, Rani, led by CEO Mir Imran who shared the story on LinkedIn, revealed that its RaniPill performed as expected […]
Vascular Therapies closes $17.3m financing
Vascular Therapies announced that it closed an upsized private funding round worth more than $17 million with contributions from new and existing investors. The Cresskill, N.J.–based clinical-stage biopharma company originally targeted $15 million for the financing, but finished with a total of $17.3 million raised. Get the full story at our sister site, MassDevice.
